Navigation Links
Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
Date:11/14/2011

first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement
Some of the statements included in this press release, particularly those anticipating the outcome of clinical trials and the future business prospects for Zerenex (ferric citrate), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for Zerenex; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our ongoing long-term Phase 3 clinical study the efficacy and safety of Zerenex observed in the previous Phase 2 studies and the short-te
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
8. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
9. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... LAWRENCEVILLE, N.J. , July 31, 2014  Celsion ... the Company will host a conference call to discuss ... EDT on Thursday, August 7, 2014. To participate in ... North America ) or 1-785-830-1924 (International/Toll) and ask ... (Conference Code: 8283269) to register ten minutes before the ...
(Date:7/31/2014)... , 31. Juli 2014 Marken ... Miami bekanntgegeben, um die wachsenden ... und Lateinamerika zu erfüllen. Die neu ausgebaute Einrichtung ... Proben und für die Zusammenlegung von Sendungen in ... zusätzliche Lagerkapazität bereitstellen.   Logo - ...
(Date:7/31/2014)... LAVAL, Quebec, July 31, 2014   , 2014 ... over the prior year , Overall organic growth was 4% ... facial injectable products; Bausch + Lomb grew 12% , ... increase of 43% , 2014 Second Quarter GAAP Operating ... , Highlights of the Second Quarter , Launched ...
Breaking Medicine Technology:Celsion Corporation to Hold Second Quarter 2014 Financial Results 2Marken erweitert regionales Logistikzentrum in Miami 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 26Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 27Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 28Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 29Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 30Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 31Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 32
... June 14, 2011 /PRNewswire-iReach/ -- URINOZINC® ... (Photo:   http://photos.prnewswire.com/prnh/20110614/CG20097 ) ... available at all corporate-owned GNC Live Well stores ... 1935, GNC has more than 6,000 stores spread ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... filed an Abbreviated New Drug Application (ANDA) with ... approval to market Olopatadine Hydrochloride Ophthalmic Solution USP, ... is a generic version of Alcon, Inc.,s Pataday™ ...
Cached Medicine Technology:Patented URINOZINC® Prostate Formula Now Available at GNC Stores 2Patented URINOZINC® Prostate Formula Now Available at GNC Stores 3Watson Confirms Pataday™ Patent Challenge 2Watson Confirms Pataday™ Patent Challenge 3
(Date:7/31/2014)... (PRWEB) July 31, 2014 Ticket Down ... at Levi’s Stadium in Santa Clara, California. Fans in the ... see some of the best club and national teams in the ... to Brazil, this has become the best time to be a ... and special events being held on American soil this year, as ...
(Date:7/31/2014)... 2014 David Kekich, anti-aging icon ... ) is thrilled that the acceptance of his ... Artificial Intelligence (AI) algorithms and then screening thousands ... acceptance. , “It took longer than ... proof is in," said Kekich. "Client acceptance is ...
(Date:7/31/2014)... July 31, 2014 Much of the liver,s metabolic ... body clock and UC Irvine researchers have now ... The study, published online today in Cell , ... metabolism and points the way to more focused drug ... obesity and diabetes. , Paolo Sassone-Corsi, UCI,s Donald Bren ...
(Date:7/31/2014)... July 31, 2014 BioProcess ... delivering cutting-edge information focused on the development ... launched its newly designed website, http://www.bioprocessintl.com ... by providing visitors specialized content under upstream ... business areas. As the site is updated ...
(Date:7/31/2014)... -- Many teens never outgrow their "growing pains," according ... for years, affecting teens, participation in sports and other ... growing pains can become chronic, the researchers cautioned. ... three young people between the ages of 12 and ... Michael Skovdal Rathleff, a physiotherapist from Aarhus University. "Seven ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 2Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 3Health News:MaxLife Solution™ Expands Distribution Globally for Breakthrough Anti-Inflammatory Support Supplement – InflaGene™ 2Health News:Strict genomic partitioning by biological clock separates key metabolic functions 2Health News:BioProcess International Launches New Website 2Health News:Teen 'Growing Pains' May Persist For Years 2
... University of Southern ... Angeles County Hospital, STEINBACH, Manitoba, Feb. 4 Partnered ... of Santa Monica, MCM,served as the millwork provider for the ... highly detailed work involving a large,number of custom nursing stations ...
... MCM,s Biggest Project Completed With Detailed Precision, ... a joint,venture of Pei Architects and Perkins & ... replacement hospital in Westwood, the Ronald,Reagan UCLA Medical ... Angeles,California. Featuring over 70,000 square feet of wall ...
... deficits , , MONDAY, Feb. 4 (HealthDay News) -- Eye ... during pregnancy but who don,t have the distinctive facial ... suggests. , "Eyeblink conditioning (EBC) is a Pavlovian ... such as a tone, with an unconditioned stimulus, such ...
... Renowned esthetician, Karen,Dunlap, has developed an advanced ... the number-one most nutritious and powerful food,in the ... between science and,nature, Dunlap discovered that topical application ... its benefits. Her new signature facial, the,Acai Berry ...
... Progen,Pharmaceuticals, Management Team (ASX: PGL; Nasdaq: PGLA) will ... 9.00am,Australian (Sydney time) and Monday 4 February at 5:00pm ... overview of the Cellgate, Inc.,acquisition and will be available ... refer to the relevant presentation at: http://www.progen-pharma.com , ...
... Trust for America,s,Health warns that the proposed 7 percent ... (CDC) in the president,s fiscal year 2009,budget could harm ... CDC would fall to a six year low for ... are skyrocketing, we should be,investing more to keep Americans ...
Cached Medicine News:Health News:MCM Completes LAC+USC Replacement Medical Facility Project 2Health News:Eye Blinks May ID Fetal Alcohol Exposure 2Health News:Breakthrough 'Acai Berry Anti-Aging Facial' Applies Benefits of Nature's Super-Food to the Skin 2Health News:Progen Investor Teleconference Dial In Details 2Health News:Cuts to HHS Could Leave Americans' Health in Critical Condition, TFAH Says; New Poll Shows Americans Believe Disease Prevention is Key to Reducing Healthcare Costs 2
... The iCycler thermal cycler maximizes what ... laboratory. It features multiple sample formats, an ... direct upgradability to real-time quantitative PCR. The ... of what a thermal cycler can do ...
... small footprint, simple intuitive programming and almost ... the ideal personal cycler in the modern ... and the self-adjusting heated lid allows a ... vessels or a microplate of 5 x ...
... The system includes: Mx3005P instrument ... choice of five (5) filters. The ... I (492nm-516nm), HEX/JOE/VIC (535nm-555nm), ROX/Texas Red ... Also included: desktop computer, Mx3005P analysis ...
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
Medicine Products: